Abstract
Purpose :
As diagnostic and therapeutic advances continue to enhance longevity in patients with lacrimal squamous cell neoplasms (LSCN), comparative second primary malignancies (SPM) are showcasing increasing relevance in long-term management. Current market analysis demonstrates lack of SPM characterization in LSCN. This retrospective cohort analysis evaluates SPMs and latency periods in patients with LSCN.
Methods :
The Surveillance, Epidemiology, and End Results (SEER) Program acted as provision for cases of first primary LSCN from 2000 to 2015. Standardized incidence ratios (SIR), excess absolute risk (EAR), were extracted, computed, and analyzed via multiple outcome analysis within the SEER software. Strict utilization of index records was performed. 95% confidence intervals (CI) are provided with statistical significance achieved at p < 0.05.
Results :
Extraction of 132 patients diagnosed with LSCN revealed mean(+/-SD) age of 62.20 (+/-12.52) years with distribution of sex as 41.66% (55) female and 58.34% (77) male. Within the sub-cohort of patients afflicted with SPM, mean age upon diagnosis of SPM is 61.08 years. Relative to the US general population, patients diagnosed with LSCN demonstrated significantly increased risk for SPM on multiple fronts. Cumulative SPM (SIR 5.63, CI 3.22 – 9.15, EAR 256.52), ocular & orbital SPM (SIR 7205.07, CI 3294.62 – 13677.47, EAR 175.42), and non-epithelial skin SPM (SIR 193.34, CI 39.87 – 565.02, EAR 58.18) showcased statistically significant increases in overall SPM occurrence at 5- and 10-years post-LSCN diagnosis.
Conclusions :
In contrast to the US general population, diagnosis of LSCN entails heightened propensity for development of second primary malignancy, including ocular, orbital, and non-epithelial skin cancers. Diagnostic and therapeutic advancements pertaining to LSCN prolong quality and longevity of patient life, thereby emphasizing the need for long-term risk management via real-time reconnaissance of malignancy-related signs and symptoms.
This is a 2021 ARVO Annual Meeting abstract.